Diplomat Pharmacy (DPLO) Receives a Hold from Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser maintained a Hold rating on Diplomat Pharmacy (DPLO) today and set a price target of $18. The company’s shares closed on Friday at $15.48, close to its 52-week low of $13.31.
According to TipRanks.com, Goldwasser is a 3-star analyst with an average return of 3.0% and a 56.2% success rate. Goldwasser covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Quest Diagnostics Inc, and Charles River Labs.
The word on The Street in general, suggests a Hold analyst consensus rating for Diplomat Pharmacy with a $17.40 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.74 and a one-year low of $13.31. Currently, Diplomat Pharmacy has an average volume of 930.1K.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diplomat Pharmacy, Inc. engages in the provision of pharmacy services. It focuses on improving the lives of patients with complex chronic diseases while delivering solutions for manufacturers, hospitals, payers, and providers.The company was founded by Dale Hagerman and Philip Hagerman in 1975 and is headquartered in Flint, MI.